Sygnature Discovery

SEPTEMBER 12, 2024

With capabilities across X-ray Crystallography Crystallisation/co-crystallisation screening of proteins, DNA, and RNA using in-house and commercial screens at various temperature. Nanoliter drop dispenser is used to rapidly screen hundreds of conditions with minimum amount of sample.

Fragment Screening 52

Fragment Screening RNA Protein Production DNA 52

Dark Matter Blog

APRIL 4, 2023

The bulk of my nearly three decades of experience up to that point was with drugging protein targets using a variety of modalities, but principally small molecules. It’s all well and good to say, “we should drug RNA,” but which RNA? And unproductive interactions between the RNA target and the DNA barcodes complicated DEL screening.

Small Molecule 52

Small Molecule RNA Fragment Screening DNA 52

Sygnature Discovery

JUNE 17, 2024

At Sygnature Discovery, we see biophysics as a core component of drug discovery projects, which can generate data throughout the pipeline. Comprehensive Assay Development for Diverse Applications Our team here at Sygnature Discovery, comprised of expert biophysicists, is highly experienced in a variety of target classes and drug modalities.

Biophysical Assays 52

Biophysical Assays Screening Hits Assay Development Fragment Screening 52

Sygnature Discovery

JUNE 17, 2024

At Sygnature Discovery, we utilise various biophysical technologies to create assays for diverse targets, integral to every stage of the drug discovery process, from hit identification to candidate selection. MST is notably effective for DNA binding proteins, where it outperforms flow-based systems in multi-component assay setups.

Small Molecule 52

Small Molecule Fragment Screening DNA Science 52